It has been published in The Journal of Allergy and Clinical Immunology the article:

“Novel vaccines targeting dendritic cells by coupling allergoids to nonoxidized mannan enhance allergen uptake and induce functional regulatory T cells through programmed death ligand 1”

The article describes the functional properties of novel allergoids performed by crosslinking allergens and mannan from Saccharomyces cerevisae. The resulting allergen-mannan conjugates were investigated both in vitro and in vivo in comparison with unconjugated allergens. The immunomodulating features of these conjugates make them suitable for more effective and safer allergen vaccines targeting dendrtitic cells which are currently under clinical development by INMUNOTEK.

The study was performed by researchers from the School of Chemistry-UCM (Universidad Complutense de Madrid), the School of Medicine-UCM, the CIB-CSIC (Biological Research Center, Superior Council for Scientific Research), the San Carlos Hospital of Madrid, Clinica Subiza, and the R&D Department of INMUNOTEK.

The project has received funding from the CDTI (Centre for the Development of Industrial Technology), Ministry of Energy and Competitiveness, Spain.

• To download the article please click here.
• The structural features of these novel glycoconjugates are described in a previous paper. To download it, please click here.

---